Attend a Webinar on a Safer, Self-Administered Injectable Contraceptive Available for Licensing
Would you be interested in bringing a new, safer, long-lasting, self-administered injectable contraceptive to market? This technology is available for licensing or co-development with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This technology is an injectable contraceptive formulation of levonorgestrel butanoate (LB), which is a hormone called a progestin. This addresses the demand for estrogen-free contraception. Injectables have a lower fail rate than combined hormonal birth control pills or patches or progestin-only pills, and this injectable can be self-injected, removing the need for a medical office visit.
This technology has concluded a Phase I subcutaneous study, and results indicate promise as a long-lasting, reversible, injectable female contraceptive. Patients in the study did not report side effects associated with other contraceptives such as weight gain or mood swings.
Other competitive advantages of this technology include:
- Safer for women with high-risk conditions.
- Self-subcutaneous and reversible injectable.
- Long-lasting contraceptive effects.
- Increased stability relative to previous formulations.
- Amenable to large-scale manufacture relative to previous formulations.
- Estrogen free contraceptive.
- Progestin only self-injectable contraceptive.
Commercial applications of this technology include:
- Injectable contraceptive use by humans.
- Use in the treatment of progestin-related diseases.
If you are interested in reading more, please view the abstract for this injectable contraceptive.
If you are interested in learning more or speaking with the inventors, Diana Blithe, Ph.D., and Min S. Lee, Ph.D., please attend the upcoming free NIH webinar. The inventors will discuss the technology itself and the results of NICHD’s completed Phase I Clinical Trial. You can register for the webinar here.